Exact Sciences Corp. (NASDAQ:EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium® (SABCS®) supporting the clinical value of the Oncotype DX Breast Recurrence Score test. New analyses presented at the meeting include an oral presentation of updated data from the RxPONDER study led by the independent SWOG Cancer Research Network, and sponsored by the National Cancer Institute (NCI). "New findings presented at SABCS 2021 add to the wealth of data highlighting the role of the Oncotype DX® test in providing critical information to personalize and improve the quality...